Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NUVB Nuvation Bio, Inc.

Not Yet Opened 04-21 16:00:00 EDT

5.11

-0.01

-0.20%

盘后5.22

+0.11+2.15%

19:58 EDT

High5.25	Low5.03	Vol3.59M
Open5.14	D1 Closing5.12	Amplitude4.30%
Mkt Cap1.78B	Tradable Cap1.18B	Total Shares347.60M
T/O18.42M	T/O Rate1.55%	Tradable Shares231.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NUVB","market":"US","secType":"STK","nameCN":"Nuvation Bio, Inc.","latestPrice":5.11,"timestamp":1776801600000,"preClose":5.12,"halted":0,"volume":3590540,"hourTrading":{"tag":"盘后","latestPrice":5.22,"preClose":5.11,"latestTime":"19:58 EDT","volume":80816,"amount":413596.2902,"timestamp":1776815929489,"change":0.11,"changeRate":0.021526,"amplitude":0.029354},"delay":0,"changeRate":-0.0019531249999999584,"floatShares":231046340,"shares":347597289,"eps":-0.6,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"04-21 16:00:00 EDT","open":5.14,"high":5.25,"low":5.03,"amount":18418662.328500003,"amplitude":0.042969,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.6,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776844800000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":5.12,"preHourTrading":{"tag":"盘前","latestPrice":5.2,"preClose":5.12,"latestTime":"09:25 EDT","volume":10172,"amount":52648.517329999995,"timestamp":1776777913783,"change":0.08,"changeRate":0.015625,"amplitude":0.015625},"postHourTrading":{"tag":"盘后","latestPrice":5.22,"preClose":5.11,"latestTime":"19:58 EDT","volume":80816,"amount":413596.2902,"timestamp":1776815929489,"change":0.11,"changeRate":0.021526,"amplitude":0.029354},"volumeRatio":1.178999,"impliedVol":0.4256,"impliedVolPercentile":0.0518},"requestUrl":"/m/hq/s/NUVB","defaultTab":"news","newsList":[{"id":"2629550068","title":"Nuvation Bio Chief Regulatory Officer Kerry Wentworth sells 36,750 shares for $184,279","url":"https://stock-news.laohu8.com/highlight/detail?id=2629550068","media":"Reuters","labels":["shareholding","insiderTrades"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2629550068?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:36","pubTimestamp":1776803802,"startTime":"0","endTime":"0","summary":"Nuvation Bio Chief Regulatory Officer Kerry Wentworth exercised stock options for 36,750 Class A common shares at USD 2.93 on April 17, 2026.Directly held Class A common shares totaled 53,000 following transactions.Stock options beneficially owned totaled 215,250 following option exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL6p382W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nuvation Bio Chief Regulatory Officer Kerry Wentworth sells 36,750 shares for $184,279","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629066593","title":"Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI","url":"https://stock-news.laohu8.com/highlight/detail?id=2629066593","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629066593?lang=en_us&edition=fundamental","pubTime":"2026-04-22 06:05","pubTimestamp":1776809115,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) announced results from a pooled analysis of long-term follow-up data from the pivotal TRUST-I and TRUST-II trials for IBTROZI, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-reports-results-from-trust-i-and-trust-ii-trials-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-reports-results-from-trust-i-and-trust-ii-trials-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629065231","title":"Nuvation Bio publishes corporate presentation on IBTROZI launch, oncology pipeline updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2629065231","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629065231?lang=en_us&edition=fundamental","pubTime":"2026-04-22 06:04","pubTimestamp":1776809083,"startTime":"0","endTime":"0","summary":"Nuvation Bio highlighted IBTROZI  as a commercial-stage growth driver, with U.S. FDA clearance for advanced ROS1+ NSCLC in June 2025.IBTROZI generated USD 24.7 million in U.S. net product revenue in 2025.Pipeline focus centered on safusidenib, an IDH1 inhibitor enrolling in pivotal SIGMA study for high-risk or high-grade IDH1-mutant astrocytoma.Company outlined pro forma cash balance of about USD 589 million, including USD 529.2 million as of Dec. 31, 2025.Presentation also flagged preclinical work from proprietary Drug-Drug Conjugate platform for solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on April 21, 2026, and is solely responsible for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL21FtpW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629065489","title":"Nuvation Bio says pooled TRUST data show 49.7-month IBTROZI response duration","url":"https://stock-news.laohu8.com/highlight/detail?id=2629065489","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629065489?lang=en_us&edition=fundamental","pubTime":"2026-04-22 06:00","pubTimestamp":1776808850,"startTime":"0","endTime":"0","summary":"Nuvation Bio reported longer-term pooled follow-up from pivotal TRUST-I and TRUST-II studies of IBTROZI  in advanced ROS1-positive NSCLC, with results already presented at AACR 2026.Data showed responses remained durable in patients who had not previously received a ROS1 TKI, supporting IBTROZI’s positioning as a front-line option.Updated analyses also showed continued activity in patients previously treated with earlier ROS1 inhibitors, reinforcing use in later-line settings.Safety remained manageable with no new signals in longer follow-up, supporting sustained treatment use.TRUST-I results were simultaneously published in Journal of Clinical Oncology.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL6YyPGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629685680","title":"Nuvation Bio CMO Liu Dongfang disposes 50,000 common shares for $251,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2629685680","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629685680?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:35","pubTimestamp":1776803704,"startTime":"0","endTime":"0","summary":"Nuvation Bio Chief Medical Officer Liu Dongfang exercised stock options for 50,000 Class A common shares at USD 1.94 on April 17, 2026.Liu sold 50,000 Class A common shares at a weighted-average price of USD 5.02 on April 17, 2026.Directly held Class A common shares totaled 18,000 following transactions.Stock options beneficially owned totaled 430,000 following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL7kLyyS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629771967","title":"Nuvation Bio publishes 2025 annual report to stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2629771967","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629771967?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:50","pubTimestamp":1776721826,"startTime":"0","endTime":"0","summary":"Nuvation Bio annual report for fiscal year ended Dec. 31, 2025 highlighted U.S. commercial launch of IBTROZI in June 2025 following FDA clearance on June 11 for adult patients with locally advanced or metastatic ROS1+ NSCLC.Company positioned IBTROZI as potential new standard of care, citing durable responses with pooled median duration of response reaching 50 months based on August 2025 cutoff from TRUST-I and TRUST-II studies.Development program expanded with first patient enrolled in September 2025 in TRUST-IV, a global Phase 3 adjuvant study in resected ROS1+ early-stage NSCLC.Pipeline focus included safusidenib, with SIGMA Phase 3 trial underway for maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma versus placebo.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL4GrFxY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629751977","title":"Nuvation Bio schedules first-quarter financial results call and webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2629751977","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629751977?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:06","pubTimestamp":1776715579,"startTime":"0","endTime":"0","summary":"Nuvation Bio will host conference call and webcast May 4, 2026 at 4:30 p.m. ET to discuss first-quarter 2026 financial results.Live webcast registration will be available via Investor Relations website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLG2WHh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629775978","title":"Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629775978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629775978?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:05","pubTimestamp":1776715501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUA3QPYZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628758497","title":"A Look At Nuvation Bio’s Valuation As Ibtrozi Uptake And Q1 Earnings Expectations Gain Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=2628758497","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628758497?lang=en_us&edition=fundamental","pubTime":"2026-04-18 21:07","pubTimestamp":1776517622,"startTime":"0","endTime":"0","summary":"Renewed attention on Nuvation Bio (NUVB) is building ahead of its upcoming Q1 earnings, as recent analyst commentary focuses on Ibtrozi’s early commercial uptake and the company’s efforts to widen the drug’s reach globally.\nSee our latest analysis for Nuvation Bio.\nNuvation Bio’s share price has recently picked up, with a 1 day share price return of 5.61% and 30 day share price return of 18.69%. However, year to date the share price return is a 40.79% decline, while the 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/a-look-at-nuvation-bios-valuation-as-ibtrozi-uptake-and-q1-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/a-look-at-nuvation-bios-valuation-as-ibtrozi-uptake-and-q1-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627821487","title":"Nuvation Bio's Ibtrozi Gains Frontline Momentum Ahead of Key Q1 Print, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2627821487","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627821487?lang=en_us&edition=fundamental","pubTime":"2026-04-16 22:53","pubTimestamp":1776351239,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) is approaching its Q1 earnings as an important checkpoint for the commercial trajectory of its ROS1 inhibitor Ibtrozi, with early signs of accelerating uptake and potential expansi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627169112","title":"Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2627169112","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627169112?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:41","pubTimestamp":1776346860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2026 09:41 ET (13:41 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213338","title":"Nuvation Bio (NUVB) Gets a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627213338?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:36","pubTimestamp":1776343014,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Buy rating on Nuvation Bio today and set a price target of $11.00. According to TipRanks, Nierengar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nuvation-bio-nuvb-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nuvation-bio-nuvb-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626119953","title":"Nuvation Bio announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2626119953","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626119953?lang=en_us&edition=fundamental","pubTime":"2026-04-10 23:25","pubTimestamp":1775834714,"startTime":"0","endTime":"0","summary":"Nuvation Bio schedules annual shareholder meeting via live audio webcast on May 21, 2026.Shareholders will vote on election of three directors to serve until 2029.Advisory vote on compensation for named executive officers is also on agenda.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL73PWMb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626922198","title":"Nuvation Bio Chief Regulatory Officer Kerry Wentworth disposes 200,000 shares for $903,560","url":"https://stock-news.laohu8.com/highlight/detail?id=2626922198","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626922198?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:23","pubTimestamp":1775679833,"startTime":"0","endTime":"0","summary":"Nuvation Bio Chief Regulatory Officer Kerry Wentworth cut direct holdings in Class A common stock to 53,000 shares in transactions dated April 6, 2026.Wentworth sold 200,000 shares at a weighted-average price of USD 4.52.He exercised stock options for 200,000 shares at USD 1.87 and USD 1.94.Wentworth held 700,000 stock options following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL39s5Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nuvation Bio Chief Regulatory Officer Kerry Wentworth disposes 200,000 shares for $903,560","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930509","title":"RBC Capital Sticks to Their Buy Rating for Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930509","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930509?lang=en_us&edition=fundamental","pubTime":"2026-04-08 09:50","pubTimestamp":1775613009,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on Nuvation Bio on April 6 and set a price target of $20.00. The company’s shares close...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625601036","title":"JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625601036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625601036?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:40","pubTimestamp":1775508051,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Nuvation Bio, with a price target of $12.00. Roy covers the Hea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676119","title":"RBC Raises Price Target on Nuvation Bio to $20 From $13, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676119","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676119?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:28","pubTimestamp":1775474928,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) has an average rating of buy and mean price target of $12.30, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625267338","title":"Nuvation Bio Inc : RBC Raises Target Price to $20 From $13","url":"https://stock-news.laohu8.com/highlight/detail?id=2625267338","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625267338?lang=en_us&edition=fundamental","pubTime":"2026-04-06 17:33","pubTimestamp":1775468008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P052:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625062049","title":"U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio","url":"https://stock-news.laohu8.com/highlight/detail?id=2625062049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625062049?lang=en_us&edition=fundamental","pubTime":"2026-04-06 16:06","pubTimestamp":1775462816,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, TwilioApril 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including EQT, Las Vegas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL8N40P08F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DLLL","TRDA","KTUP","PJT","BKNU","KTOS","AMDU","LVS","EVR","HLI","ASH","BOOT","GSX","LNN","NTRS","EQT","AMYY","AMD","AMUU","AEYE","AMKR","POWI","MRK","CCO","CAR","BKNG","LONA","IBKR","AMDG","DELL","NUVB","AMDW","DAMD","DOW","BK","EXPE","NXST","SCHW","LPCN","ADM","AMDY","AMP","AMDL","LAZ","LPLA","GLW","PRIM","COHU","MC","AYI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664666","title":"Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664666","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664666?lang=en_us&edition=fundamental","pubTime":"2026-04-04 03:24","pubTimestamp":1775244283,"startTime":"0","endTime":"0","summary":"In March 2026, Eisai and Nuvation Bio reported that the European Medicines Agency validated their Marketing Authorisation Application for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer, following existing approvals in the US, China and Japan.\nThis regulatory milestone could broaden taletrectinib’s geographic reach under Eisai’s licensing deal, potentially deepening Nuvation Bio’s role in targeted lung cancer treatment across Europe and other Eisai territories.\nWe’ll...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/is-ema-validation-of-taletrectinib-expanding-nuvation-bios-n","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/is-ema-validation-of-taletrectinib-expanding-nuvation-bios-n","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4081","EMA","BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0536},{"period":"1month","weight":0.2109},{"period":"3month","weight":-0.1691},{"period":"6month","weight":0.164},{"period":"1year","weight":1.5808},{"period":"ytd","weight":-0.4297}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0856},{"period":"3month","weight":0.0273},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.3701},{"period":"ytd","weight":0.0325}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.099824},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.044723},{"month":3,"riseRate":0.5,"avgChangeRate":0.083814},{"month":4,"riseRate":0.5,"avgChangeRate":0.036267},{"month":5,"riseRate":0.6,"avgChangeRate":0.002702},{"month":6,"riseRate":0.2,"avgChangeRate":-0.090917},{"month":7,"riseRate":0.6,"avgChangeRate":0.065913},{"month":8,"riseRate":0.6,"avgChangeRate":0.013694},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038205},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.016548},{"month":11,"riseRate":0.5,"avgChangeRate":0.163132},{"month":12,"riseRate":0.666667,"avgChangeRate":0.061496}],"exchange":"NYSE","name":"Nuvation Bio, Inc.","nameEN":"Nuvation Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvation Bio, Inc.,NUVB,Nuvation Bio, Inc.股票,Nuvation Bio, Inc.股票老虎,Nuvation Bio, Inc.股票老虎国际,Nuvation Bio, Inc.行情,Nuvation Bio, Inc.股票行情,Nuvation Bio, Inc.股价,Nuvation Bio, Inc.股市,Nuvation Bio, Inc.股票价格,Nuvation Bio, Inc.股票交易,Nuvation Bio, Inc.股票购买,Nuvation Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction